HSA Singapore's Revised Voluntary Notification System for Complementary Health Products: What Brands Need to Know

Summary

• Singapore is revising its regulatory framework for health supplements, shifting to a self-declaration model for its Voluntary Notification System (VNS) on 15 July 2026, which becomes mandatory in 2028.

• This change places greater accountability on brands to ensure their products meet all HSA safety, quality, and labelling standards, even though technical documents are not required at the point of submission.

• Brands should use the voluntary period to audit their products, organize compliance documentation, and notify early to gain process familiarity and de-risk market access before the 2028 deadline.

• For brands managing multiple APAC markets, a platform like Taama can help pre-validate products against HSA's requirements, ensuring confidence before making a self-declaration.

If you sell health supplements in Singapore — or are planning to enter the market — a significant regulatory change is coming that your team needs to be across now.

Singapore's Health Sciences Authority (HSA) has revised its Voluntary Notification System (VNS) for Complementary Health Products (CHP), with the updated framework taking effect on 15 July 2026. The revision introduces a self-declaration model, streamlines the notification process, and sets the stage for what will become a mandatory CHP notification framework under the Health Products Act in 2028.

This isn't a minor administrative tweak. It's a deliberate, phased shift in how Singapore regulates the health supplement industry — one that places greater accountability squarely on brands. Understanding what's changed, and why it matters, is the first step to protecting your market access.

The Regulatory Landscape: What Are CHPs and How Are They Currently Governed?

Before diving into the changes, it's worth establishing the baseline for readers newer to Singapore's framework.

Complementary Health Products (CHPs) include health supplements and traditional medicines — products intended to supplement the diet and support health. They typically come in dosage forms such as capsules, tablets, powders, liquids, and syrups. If you're uncertain whether your product falls under this classification, HSA provides a self-help classification tool to help brands confirm their product's regulatory category.

Under Singapore's current regulatory model, health supplements do not require pre-market approval or licensing from HSA before they can be sold. However, this doesn't mean the market is unregulated. Importers, manufacturers, and distributors are legally responsible for ensuring their products meet HSA's safety, quality, and labelling standards. HSA enforces compliance through post-market surveillance — monitoring products already on shelves and acting when issues arise.

This post-market, reactive model has long been a source of concern among consumers, with some questioning whether it provides sufficient protection. It's precisely this gap that HSA's evolving regulatory approach is designed to address — moving the industry toward greater accountability and transparency before placing products on the market.

The existing VNS was introduced as a voluntary mechanism for companies to formally notify HSA of their CHPs. The revised system, effective July 2026, significantly refines how this process works.

The 2026 Revision: What's Actually Changing?

The revised VNS introduces four key changes that brand and regulatory teams need to understand in practical terms.

1. The Shift to a Self-Declaration System

This is the most consequential change. The VNS is moving from a review-based process — where HSA assessed submitted documents — to a self-declaration model.

Under the new system, companies will not be required to submit supporting technical documents at the point of notification. Specifically, the following documents are no longer required upfront:

• Certificate of Analysis (CoA)

• Manufacturer Licences

• Good Manufacturing Practice (GMP) Certificates

Instead, companies declare that their product complies with HSA's safety, quality, and labelling requirements. The documentation still needs to exist — HSA may request it during post-notification checks — but it is no longer a gate at the point of submission.

This is a significant operational shift. Details of the updated system are outlined on the HSA Voluntary Notification System page.

2. A Simplified Notification Form

Alongside the self-declaration model, the notification form itself has been streamlined. It will now capture only the essential fields needed for supply chain traceability and to support post-notification compliance checks. This reduces the administrative burden of submission while still giving HSA the data it needs to conduct effective market oversight.

The expected processing turnaround is approximately two weeks from submission.

3. A Defined Pathway for Novel or Non-Approved Ingredients

Brands working with ingredients not currently on HSA's pre-approved list are not excluded from the VNS — but there is an additional step. Companies can still submit a notification for these products; however, they must provide documentation for HSA's ingredient safety review before the product will be published on the publicly available HSA VNS notified products list.

This is a critical planning point. The ingredient safety review adds time to the process, and brands with novel formulations need to factor this into their go-to-market timelines accordingly.

4. No Fee to Notify

The VNS remains free of charge. There is no cost to notify products under this system, removing any financial barrier to early participation.

What Self-Declaration Really Means: The Compliance Burden Shifts to You

The move to a self-declaration model is not a relaxation of standards. If anything, the accountability burden on brands increases.

Under the previous review-based process, HSA's assessment of submitted documents provided a layer of external validation. With self-declaration, brands are affirming — without upfront third-party review — that their product genuinely meets HSA's regulatory requirements. If a product is found to be non-compliant during post-market surveillance, the brand bears full responsibility.

This means that before submitting a VNS notification, your regulatory team must be genuinely confident that every product in scope meets HSA's published standards. These are not vague guidelines — they include specific, quantified limits:

Heavy Metal Limits (per product):

• Arsenic: ≤ 5 ppm

• Lead: ≤ 10 ppm

• Mercury: ≤ 0.5 ppm

• Cadmium: ≤ 0.3 ppm

Microbial Limits:

• Total aerobic microbial count: ≤ 10⁵ CFU/g or CFU/ml

• Total combined yeasts and moulds count: ≤ 5 × 10² CFU/g or CFU/ml

• Absence of pathogens including E. coli and Salmonella

These limits, along with detailed labelling requirements, are outlined on the HSA Health Supplements overview page. Your Certificate of Analysis, GMP documentation, and full technical dossier still need to exist and be audit-ready — they're just no longer submitted upfront.

The practical implication: treat the self-declaration not as a rubber stamp, but as an internal compliance checkpoint. If you can't confidently verify that your product meets every applicable standard, you're not ready to notify.

The Road to 2028: Why Early Notification Is a Strategic Imperative

HSA's decision to revise the VNS now is deliberate. The agency has been transparent about its longer-term goal: a mandatory CHP notification framework under the Health Products Act, expected to come into effect in 2028.

The revised VNS is designed to serve as a transitional on-ramp — giving the industry time to familiarise itself with the notification process before it becomes compulsory. HSA is actively encouraging companies to notify early, and there are clear strategic reasons why brands should take that guidance seriously.

Early notification gives your team:

• Process familiarity. Your regulatory team will learn HSA's systems, identify any product-level gaps, and resolve them without the pressure of a compliance deadline.

• A head start on the mandatory framework. When the 2028 rules take effect, notified brands will already be in the system — rather than scrambling to meet a new requirement.

• Reduced risk. Any compliance issues discovered during the voluntary phase can be addressed quietly; once notification is mandatory, non-compliance carries far higher stakes.

• A market signal. Appearing on HSA's publicly accessible VNS list demonstrates to retailers, distributors, and consumers that your brand takes its regulatory obligations seriously — a meaningful differentiator in a market where consumer confidence in supplement oversight is still developing.

Your Action Plan: Practical Next Steps for Brands

Given the 15 July 2026 effective date, here's what your team should be doing now.

Step 1: Confirm Your Product Classification

Use HSA's self-help CHP classification tool to confirm that your products fall within the CHP category and are therefore within the scope of the VNS. This is the logical starting point before any compliance work begins.

Step 2: Conduct a Full Compliance Review

Audit your entire CHP portfolio against HSA's safety, quality, and labelling requirements. Ensure your technical dossier — including CoA, GMP certificates, and manufacturer documentation — is complete, current, and organised for each product. Remember: these documents don't go to HSA at notification, but they must be available if requested.

Step 3: Build a Timeline for Products with Novel Ingredients

If any of your products contain ingredients not currently on HSA's pre-approved list, treat those as a separate workstream. The additional ingredient safety review required before publication on the VNS list adds time to your process. Work backwards from your intended launch date and ensure your submission is made early enough to absorb this step.

Step 4: Submit Your Notifications Early

Once the revised system is live on 15 July 2026, prioritise notifying your products. Notifications are submitted via https://go.gov.sg/vns. With an expected two-week turnaround, early submission means early listing — and early de-risking.

Step 5: Maintain Audit-Ready Records

Establish and maintain an internal system for storing all compliance documentation linked to each notified product. Post-market checks are a real enforcement mechanism, and disorganised documentation is an unnecessary liability.

Managing Multi-Market Compliance with Confidence

For brands operating across APAC, Singapore is rarely the only regulatory jurisdiction on the table. Managing compliance across multiple markets simultaneously — each with its own classification rules, ingredient restrictions, and labelling requirements — is genuinely complex. The shift to self-declaration in Singapore adds another layer of internal rigour to that process.

This is where specialist compliance platforms can make a meaningful difference. Rather than relying on fragmented internal knowledge or market-by-market consultants, brands can use structured tools to assess product compliance against the specific standards applicable in each jurisdiction before making any regulatory submission.

For brands managing Singapore alongside other APAC markets, Taama's multi-market compliance assessment covers Singapore's HSA classification and labelling requirements — helping teams verify that their product genuinely meets the self-declaration standard before they submit to HSA. This kind of pre-validation is precisely what the self-declaration model demands: internal confidence before you make the declaration.

The Bottom Line

The HSA's revised Voluntary Notification System represents a meaningful evolution in Singapore's regulatory approach to Complementary Health Products. The shift to self-declaration is not a relaxation — it's a redistribution of responsibility. Brands that previously relied on the document review process as a compliance checkpoint now need to build that rigour internally.

The opportunity is clear: the revised VNS is your low-friction, no-cost pathway to get ahead of the mandatory 2028 framework. Use the voluntary phase to stress-test your compliance posture, familiarise your team with HSA's systems, and get your products formally listed before notification becomes a legal requirement.

Brands that treat this as a strategic priority now will be the ones best positioned when Singapore's mandatory CHP framework arrives. Those that wait may find themselves under pressure to comply with a compulsory system they've never navigated before — and with considerably less margin for error.

Start the process early. The window is open, there's no cost to enter, and the 2028 deadline will arrive faster than it looks.

Frequently Asked Questions

What is the biggest change in Singapore's new health supplement regulations?

The biggest change is the shift to a self-declaration model for the Voluntary Notification System (VNS) for Complementary Health Products (CHPs), which takes effect on 15 July 2026. Instead of the Health Sciences Authority (HSA) reviewing technical documents like Certificates of Analysis upfront, companies will now declare that their products meet all safety, quality, and labelling standards. This system will become mandatory in 2028.

When does the revised VNS become mandatory?

The revised VNS becomes mandatory in 2028. The voluntary phase, which uses the new self-declaration model, begins on 15 July 2026. This two-year period is designed to give brands time to adapt to the new process before notification becomes a legal requirement under the Health Products Act.

Who is responsible for compliance under the self-declaration model?

The brand, importer, manufacturer, or distributor placing the product on the Singapore market is fully responsible for ensuring compliance. The self-declaration model places greater accountability directly on companies. While you don't submit all technical documents at the point of notification, you must have them organised and ready for post-market audits by the HSA.

Do I still need to prepare technical documents like a Certificate of Analysis (CoA)?

Yes, you must still prepare and maintain all necessary technical documents, even though they are not required for the initial submission. Documents such as the Certificate of Analysis (CoA), Good Manufacturing Practice (GMP) certificates, and manufacturer licences are essential. The HSA can request this documentation at any time during post-market surveillance to verify your product's compliance.

Why should I notify my products before the 2028 mandatory deadline?

Notifying early helps you de-risk your market access by familiarising your team with the process and identifying any compliance gaps without the pressure of a hard deadline. Early participation allows your team to understand HSA's systems, resolve any issues quietly, and get your products listed on the public VNS list. This signals to consumers and partners that you are prepared for the mandatory framework.

How can I check if my product is classified as a Complementary Health Product (CHP)?

You can use the Health Sciences Authority's (HSA) official self-help classification tool to determine if your product falls under the CHP category. This is a critical first step, as the VNS framework specifically applies to CHPs, which include health supplements and traditional medicines. The tool is available on the HSA website.